Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Oncogenesis
SJR: 0.946 SNIP: 0.503 CiteScore™: 2

ISSN Imprimir: 0893-9675
ISSN En Línea: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2017024695
pages 283-301

Oncogenic RAS: From Its Activation to Its Direct Targeting

Apostolos Zaravinos
Biomedical Sciences Program, Department of Life Sciences, School of Sciences, European University Cyprus, 1516 Nicosia, Cyprus

SINOPSIS

The RAS oncogenes are the most commonly mutated genes across human cancers. This review is a look back at the discovery of the RAS genes, how we came to understand their function, and how these oncogenes are aberrantly activated, driving cancer development and growth. It also highlights the comprehensive efforts made during the last 30 years to develop therapeutic strategies against the oncogenic mutant RAS. Although there have been many lost battles in the war against mutant RAS-bearing cancer cells, and we have yet to determine which is the "best" path for inhibition of the mutated RAS, a better understanding of the protein's structure combined with technological advances in the field has allowed the development of new strategies to make anti-RAS therapies a reality. The state-of-the-art for each strategy is discussed, focusing on the promises and potential pitfalls of each of them.


Articles with similar content:

Gene Expression in Stem Cells
Critical Reviews™ in Eukaryotic Gene Expression, Vol.19, 2009, issue 4
Yu Liang, Criss Walworth, Iain Russell, Caifu Chen
IAPs: Mediators of Oncogenesis and Targets for Anticancer Therapy
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Ali Bettaieb, Stéphanie Plenchette, Laurence Dubrez, Sarra Bouaouiche
Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma
Critical Reviews™ in Biomedical Engineering, Vol.40, 2012, issue 4
Frank O. Nestle, Louise Saul, Sophia N. Karagiannis, Sophia Tsoka, Debra H. Josephs, Chrysanthi Ainali, Panagiotis Karagiannis
YY1 Is an Inducer of Cancer Metastasis
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 1-2
Guangchao Sui, Dangdang Li, Wenmeng Wang